Photocure ASA, a Norwegian company that has developed a photosensitive method of killing cancer cells, is ‘de-merging’ its 91.4%-owned subsidiary, PCI Biotech, by distributing shares in the subsidiary to its existing shareholders on a one-for-one basis.
